No Data
No Data
BofA Securities Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Cuts Target Price to $52
Express News | Agios Pharmaceuticals Inc : BofA Global Research Cuts Price Objective to $52 From $54
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer
Celldex Therapeutics and Agios Pharmaceuticals to Present at March 2025 Investor Conferences
J.P. Morgan Maintains Agios Pharmaceuticals(AGIO.US) With Hold Rating, Raises Target Price to $43
Agios Pharmaceuticals Price Target Maintained With a $58.00/Share by HC Wainwright & Co.